The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZYME | +98.52% | -26.9% | -6.07% | +85% |
| S&P | +17.45% | +75.43% | +11.88% | +183% |
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab’s unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
The biotech stock's shares may have been pushed by a short squeeze.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.52M | -91.9% |
| Gross Profit | $824.00K | -97.0% |
| Gross Margin | 32.76% | -55.3% |
| Market Cap | $1.99B | 95.3% |
| Market Cap / Employee | $7.52M | 111.6% |
| Employees | 264 | -7.7% |
| Net Income | -$41,209.00K | -75.3% |
| EBITDA | -$42,461.00K | -129.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $41.16M | -37.7% |
| Accounts Receivable | $4.64M | -91.7% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.80M | -6.2% |
| Short Term Debt | $3.47M | 26.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.04% | 3.5% |
| Return On Invested Capital | -30.80% | 4.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10,552.15K | 73.4% |
| Operating Free Cash Flow | -$9,982.26K | 74.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.44 | 2.71 | 3.85 | 6.23 | 122.54% |
| Price to Sales | 9.59 | 7.90 | 9.62 | 18.72 | 30.68% |
| Price to Tangible Book Value | 2.57 | 2.84 | 4.02 | 6.50 | 120.50% |
| Enterprise Value to EBITDA | -29.10 | 278.90 | -54.34 | -41.76 | -12.65% |
| Return on Equity | -29.8% | -19.9% | -18.5% | -26.7% | -12.50% |
| Total Debt | $18.46M | $18.68M | $18.90M | $18.27M | -1.29% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
